Want to see PCRX full AI Analyst Report?
PCRX Stock Chart & Stats
$25.53
$0.68(2.63%)
At close: 4:00 PM EDT
$25.53
$0.68(2.63%)
Day’s Range― - ―
52-Week Range$18.80 - $27.66
Previous CloseN/A
Volume164.31K
Average Volume (3M)624.27K
Market Cap
$1.05B
Enterprise Value$1.18K
Total Cash (Recent Filing)$251.03M
Total Debt (Recent Filing)$412.12M
Price to Earnings (P/E)74.8
Beta0.62
Next Earnings
Oct 29, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding39,861,885
10 Day Avg. Volume457,000
30 Day Avg. Volume624,268
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$28.80Price Target Upside12.81% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)2.91
Revenue Forecast (FY)$754.02M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong and improving operating and free cash flow, with cash conversion tracking reported earnings, gives Pacira internal funding capacity. Combined with $251 million of cash and investments, this supports pipeline investment and resilience while leverage improves.
Expanded Payer AccessBroader reimbursement access can support sustained product adoption by reducing customer friction across hospitals and care sites. UnitedHealthcare’s coverage expansion, alongside ZILRETTA’s preferred-list placement, strengthens Pacira’s commercial reach and utilization prospects.
Pipeline ProgressAdvancing PCRX-201 and multiple upcoming clinical readouts provide potential avenues for portfolio expansion beyond current products. Continued development can diversify future revenue sources and reinforce Pacira’s specialty focus if clinical milestones translate into later approvals.
Bears Say
Margin CompressionThe four-point gross-margin decline shows that recent revenue is converting into less operating value than a year earlier. Persistent pressure from product mix, discounting, or costs could constrain cash available for research, commercialization, and shareholder returns.
Procedure Demand ExposurePacira’s core products depend on procedure volumes and reimbursement settings, so weaker elective activity can directly limit utilization. Hospital inpatient softness is especially relevant because EXPAREL is not reimbursed outside the bundled payment, creating an ongoing demand sensitivity.
NOPAIN Reimbursement UncertaintyUncertainty around future CMS reimbursement creates a structural access risk for Pacira’s non-opioid pain franchise. If renewal or inclusion is delayed, hospitals and clinicians may face weaker economic incentives to adopt EXPAREL, limiting utilization and revenue expansion.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $18.80 and its highest was $27.66 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $1.05B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.646 by $0.084.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.71.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 39,861,885 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.73 in its last earnings report, beating expectations of $0.646. Following the earnings report the stock price went down -9.957%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.80 (12.81% Upside)
$28.80 (12.81% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 21.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$28.80
▲(12.81% Upside)
Technical Analysis
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
3.67% Insiders
24.57% Mutual Funds
21.68% Other Institutional Investors
16.01% Public Companies and
Individual Investors